ClinicalTrials.gg
RecruitingNCT07698197Updated Jul 23, 2026

Exercise Intervention and Immunodeficiency

An interventional study of App-based exercise intervention in Primary Antibody Deficiency Disorders, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Primary Immunodeficiency Diseases with a site in United States — 25 open to participants now, 34 under way, 4 of them phase 3. Primary Immunodeficiency Diseases · United States.

Planned enrollment
57th of 75
20 · median 40
Started
2026
with 1 other
No phase
7 of 108
1 open now
Primary completion
2027-07
later than 14 of 28 live
Registered
108th of 108
by date

Among the 108 studies in Primary Immunodeficiency Diseases with a site in United States, this one is the 57th largest by planned enrollment of the 75 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, reaches primary completion later than 14 of the 28 other live ones, and was the 108th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

25 of the 108 studies in Primary Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Primary Immunodeficiency Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess if a 12-week exercise program is safe, practical, and acceptable for adults with primary antibody deficiencies. It also looks at whether the program can improve the quality of life and help the immune system work better.

Read the detailed description

Study activities will include:

Completion of health questionnaires Participation in a 12-week exercise program using a mobile application Having your exercise activity tracked through the mobile application Reporting any symptoms or infections that develop Providing blood samples for immune-related testing at your patient visits. Completion of assessments at the beginning and end of study

03

Conditions studied

  • Primary Antibody Deficiency Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with one of the following primary antibody deficiencies: IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency
  • Receiving care in the Section of Rheumatology, Allergy \& Immunology
  • Able and willing to participate in a moderate-intensity exercise program. Patients will be screened using the American College of Sports Medicine (ACSM) Pre- participation Screening Guidelines. This algorithm assesses patients for cardiovascular, renal, and metabolic disease. Those patients determined to not require further medical clearance to participate in exercise will be included.

Exclusion criteria

Exclusion Criteria:

  • Receipt of immunoglobulin (Ig) replacement therapy
  • Use of or immunomodulatory medications (e.g., chronic systemic , B-cell-depleting therapies)
  • Medical to moderate-intensity exercise as determined by clinical assessment using the previously discussed ACSM Pre-participation Screening Guidelines.
  • Other risk factors/medical conditions that would limit safe participation in exercise as determined by clinical assessment, including active rheumatologic conditions including active rheumatoid arthritis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    App-based exercise intervention

    12-week, app-based exercise intervention in adults with primary antibody deficiencies with completion of survey procedures and collection of clinical and laboratory data

    Behavioral: App-based exercise intervention

Interventions

  • BehavioralApp-based exercise intervention

    12 week structured moderate-intensity exercise intervention delivered via a mobile application

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    Number and proportion of eligible individuals who enroll

    Time frame: Day 1

  2. Retention rate

    Number of enrolled participants who complete the 12-week study

    Time frame: 12 weeks

  3. Frequency of app usage- Adherence

    Mean number of times app was utilized

    Time frame: 12 weeks

  4. Duration of workout- Adherence

    Mean duration of workout in minutes

    Time frame: 12 weeks

  5. Mean score Borg Scale of Rating of Perceived Exertion

    Measures exertion on a total scale of 0 (no exertion or resting) to 10 (pushing yourself to the max).

    Time frame: 12 weeks

  6. Data completeness

    Proportion of expected study data successfully collected at each time point

    Time frame: 12 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 13, 2026
StartActual
Jul 17, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698197
Lead sponsor
Yale University
Collaborators
The Pump
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Jul 17, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

Ryan Steele, DO, MSc
Contact
r.steele@yale.edu
203-785-7092 ext. 57092
Ryan Steele, DO, MSc
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion